Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net income	$ 106,500	$ 379,200
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation	500	200
Gain on sale of patents		(269,800)
Changes in allowance for doubtful accounts	1,500	5,900
Unrealized (gain) loss from marketable securities	55,600	(14,200)
Changes in operating assets and liabilities:
Accounts receivable	(52,800)	(145,600)
Prepaid expenses and other current assets	(27,300)	(22,300)
Accounts payable and accrued expenses	(20,300)	(17,700)
Lease liabilities	(200)
Deferred revenue	214,500	78,000
Net cash provided by operating activities	278,000	(6,300)
Cash flows from investing activities
Purchase of marketable securities		(242,600)
Proceeds from sale of patents		269,800
Purchase of property and equipment		(3,400)
Net cash used by investing activities		23,800
Net change in cash	278,000	17,500
Cash and cash equivalents, beginning of the period	4,755,300	4,375,300
Cash and cash equivalents, end of the period	$ 5,033,300	$ 4,392,800